Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
about
Biomarkers of Angiogenesis in Colorectal CancerDecreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsSerine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerBevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery diseaseRamucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapyAlternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.Detection of VEGF-A(xxx)b isoforms in human tissuesA plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancerPredictive biomarkers to anti-VEGF therapy: progress toward an elusive goalTranslational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.Understanding and targeting resistance to anti-angiogenic therapies.Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.TRPM8: a potential target for cancer treatment.Pharmacology of Modulators of Alternative Splicing.Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer.Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A.Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratiosSequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma.Growth of Uveal Melanoma following Intravitreal Bevacizumab."Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma.
P2860
Q26778891-54130355-353A-4BB9-A87B-C16E40C73713Q27853168-5ED39F78-76E5-4521-A8A1-07992F8AA7A5Q28251240-2A6061AE-AAD9-4234-B74D-FFE1E0730AA5Q33620736-0D97C86B-E313-41E1-A0B2-DB792AA84789Q34641120-AE6ABEBE-2495-4D33-BBAB-4FACFD63AC9EQ34671886-30DE618F-F837-40F1-B46A-8F127B9A9961Q34792239-B22681AF-0AD9-48EB-BFFD-595384DAB575Q34854858-C9D1E201-B365-4B54-A496-A61704463987Q34918179-CDD47784-3827-42DD-B5E5-3EA90CC82FC8Q36333585-D70451EA-B54C-4267-A47D-5D5732623F6CQ36632312-04B5458E-54E5-4E83-8573-5D9001D72C2BQ36910794-5C2F73F3-4349-4B74-91C8-C38FB3939FFEQ37054876-4F0AE8D3-D440-455E-B31E-3DD141B75043Q37705932-6DB506CE-A674-477B-9D58-0AFF60F90A93Q38133568-D5C74116-FA41-422F-939E-EBED683234C2Q38317180-B5D7C5F0-ADE3-4396-BDD2-3AA3709429CBQ38709214-9DE949EF-71CA-463D-BA1F-056534DBF144Q38776406-284D1F0B-4C55-4A0B-A70D-4728B66582B5Q39036253-50581E70-85F4-4C2B-971D-3997A4471772Q41892380-0D94A761-ED80-4D5B-95AB-A99D5C4CD8D8Q41949087-8C694046-665E-4D2E-B551-306BA9CBC09EQ41953953-8F6DFDB0-7FC4-42ED-8AA7-A280C1B3FA31Q42427504-FE6B16D8-6AAC-43AE-BBE2-7AF86A5810A3Q44523176-3C92B419-1049-4B51-AADD-E7DC2E59CC39Q46084068-F89DAAB4-966E-4F9A-9F6A-6F9AB374AFFEQ48207420-3A74665B-FCC5-4D62-A8B6-F66A309C1DC3Q52595509-D0A1A059-7F51-43CB-8F3E-DCAB98BA032BQ55257606-02C08669-CBAC-409E-9BAC-6808695296B8
P2860
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Association between VEGF splic ...... ents treated with bevacizumab.
@ast
Association between VEGF splic ...... ents treated with bevacizumab.
@en
type
label
Association between VEGF splic ...... ents treated with bevacizumab.
@ast
Association between VEGF splic ...... ents treated with bevacizumab.
@en
prefLabel
Association between VEGF splic ...... ents treated with bevacizumab.
@ast
Association between VEGF splic ...... ents treated with bevacizumab.
@en
P2093
P2860
P1476
Association between VEGF splic ...... ents treated with bevacizumab.
@en
P2093
Al Bowen Benson
Alex H R Varey
Bruce J Giantonio
David O Bates
Kirsty E Symonds
Neal J Meropol
Paul J Catalano
Peter J O'Dwyer
Pramila Ramani
Steven J Harper
P2860
P304
P356
10.1158/1078-0432.CCR-12-2223
P407
P577
2012-10-25T00:00:00Z